Radiochemical synthesis and preclinical evaluation of 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD)

István Hajdu, János Angyal, Dezső Szikra, István Kertész, Milo Malanga, Éva Fenyvesi, Lajos Szente, M. Vecsernyés, I. Bácskay, J. Váradi, Pálma Fehér, Zoltán Ujhelyi, Gábor Vasvári, Ágnes Rusznyák, György Trencsényi, Ferenc Fenyvesi

Research output: Contribution to journalArticle

Abstract

A new renaissance started in the research and application of cyclodextrins a few years ago. 2-Hydroxypropyl-beta-cyclodextrin (HPBCD) is used in the formulation of drugs and recently orphan designation was granted for the treatment of Niemann-Pick disease, type C. HPBCD is considered to be safe, but the exact mechanism of action and side effects are not completely explained. Labeled cyclodextrin derivatives are required to reveal the biological activity and in vivo distribution by imaging techniques. The aims of our study were to synthetize the 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD) and test the pharmacokinetic properties and in vivo distribution of this radiolabeled molecule. p-NCS-benzyl-NODA-GA (NODAGA) was conjugated to the 6-deoxy-6-monoamino-(2-hydroxypropyl)-β-cyclodextrin (NH2-HPBCD). The product (NODAGA-HPBCD) was analyzed by analytical RP-HPLC and verified with high resolution mass spectrometry. In the next step the NODAGA-HPBCD was labeled with Gallium-68 (68Ga). The 68Ga labeled NODAGA-HPBCD (68Ga-NODAGA-HPBCD) was characterized and the radiochemical purity (RCP%), partition coefficient (log P values), and in vitro stability was determined. Thereafter in vivo distribution and pharmacokinetic properties of 68Ga-NODAGA-HPBCD was monitored by positron emission tomography (PET). NODAGA-HPBCD was purified by preparative RP-HPLC and the purity was better than 98%. The radiochemical purity of the 68Ga-NODAGA-HPBCD was higher than 98%, the specific activity was 17.62 ± 2.43 GBq/μmol, and the decay corrected yield was 76.54 ± 6.12% (n = 8). The octanol/water partition coefficient of 68Ga labeled NODAGA-HPBCD was found to be −3.07 ± 0.11. In vivo dynamic and ex vivo biodistribution studies using control BALB/c mice revealed that 68Ga labeled NODAGA-HPBCD was mainly excreted by the kidney, due to its hydrophilic properties that has been proved by the partition coefficient. The accumulation of the radiotracer in abdominal organs was low, and no uptake was found in the brain. In conclusion 68Ga labeled NODAGA-HPBCD was successfully produced for the first time and tested in vitro and in vivo. The synthesized NODAGA-HPBCD was characterized and labeled with 68Ga successfully. Overall, the outcome of our study indicates that the in vivo behavior of radiolabeled cyclodextrins can be examined by PET techniques, thus these derivatives are suitable for further pharmacokinetic measurements.

Original languageEnglish
Pages (from-to)202-208
Number of pages7
JournalEuropean Journal of Pharmaceutical Sciences
Volume128
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Cyclodextrins
Pharmacokinetics
2-hydroxypropyl-beta-cyclodextrin
Positron-Emission Tomography
Type C Niemann-Pick Disease
High Pressure Liquid Chromatography
Orphan Drug Production
Octanols
Drug Compounding
Gallium
Mass Spectrometry
Outcome Assessment (Health Care)
Kidney
Water
Brain
Research
1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane
In Vitro Techniques

Keywords

  • Ga
  • Hydroxypropyl-beta-cyclodextrin
  • Pharmacokinetics
  • Positron emission tomography

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Radiochemical synthesis and preclinical evaluation of 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD). / Hajdu, István; Angyal, János; Szikra, Dezső; Kertész, István; Malanga, Milo; Fenyvesi, Éva; Szente, Lajos; Vecsernyés, M.; Bácskay, I.; Váradi, J.; Fehér, Pálma; Ujhelyi, Zoltán; Vasvári, Gábor; Rusznyák, Ágnes; Trencsényi, György; Fenyvesi, Ferenc.

In: European Journal of Pharmaceutical Sciences, Vol. 128, 01.02.2019, p. 202-208.

Research output: Contribution to journalArticle

Hajdu, I, Angyal, J, Szikra, D, Kertész, I, Malanga, M, Fenyvesi, É, Szente, L, Vecsernyés, M, Bácskay, I, Váradi, J, Fehér, P, Ujhelyi, Z, Vasvári, G, Rusznyák, Á, Trencsényi, G & Fenyvesi, F 2019, 'Radiochemical synthesis and preclinical evaluation of 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD)', European Journal of Pharmaceutical Sciences, vol. 128, pp. 202-208. https://doi.org/10.1016/j.ejps.2018.12.001
Hajdu, István ; Angyal, János ; Szikra, Dezső ; Kertész, István ; Malanga, Milo ; Fenyvesi, Éva ; Szente, Lajos ; Vecsernyés, M. ; Bácskay, I. ; Váradi, J. ; Fehér, Pálma ; Ujhelyi, Zoltán ; Vasvári, Gábor ; Rusznyák, Ágnes ; Trencsényi, György ; Fenyvesi, Ferenc. / Radiochemical synthesis and preclinical evaluation of 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD). In: European Journal of Pharmaceutical Sciences. 2019 ; Vol. 128. pp. 202-208.
@article{5f0b6190edf846738222c69789737ac4,
title = "Radiochemical synthesis and preclinical evaluation of 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD)",
abstract = "A new renaissance started in the research and application of cyclodextrins a few years ago. 2-Hydroxypropyl-beta-cyclodextrin (HPBCD) is used in the formulation of drugs and recently orphan designation was granted for the treatment of Niemann-Pick disease, type C. HPBCD is considered to be safe, but the exact mechanism of action and side effects are not completely explained. Labeled cyclodextrin derivatives are required to reveal the biological activity and in vivo distribution by imaging techniques. The aims of our study were to synthetize the 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD) and test the pharmacokinetic properties and in vivo distribution of this radiolabeled molecule. p-NCS-benzyl-NODA-GA (NODAGA) was conjugated to the 6-deoxy-6-monoamino-(2-hydroxypropyl)-β-cyclodextrin (NH2-HPBCD). The product (NODAGA-HPBCD) was analyzed by analytical RP-HPLC and verified with high resolution mass spectrometry. In the next step the NODAGA-HPBCD was labeled with Gallium-68 (68Ga). The 68Ga labeled NODAGA-HPBCD (68Ga-NODAGA-HPBCD) was characterized and the radiochemical purity (RCP{\%}), partition coefficient (log P values), and in vitro stability was determined. Thereafter in vivo distribution and pharmacokinetic properties of 68Ga-NODAGA-HPBCD was monitored by positron emission tomography (PET). NODAGA-HPBCD was purified by preparative RP-HPLC and the purity was better than 98{\%}. The radiochemical purity of the 68Ga-NODAGA-HPBCD was higher than 98{\%}, the specific activity was 17.62 ± 2.43 GBq/μmol, and the decay corrected yield was 76.54 ± 6.12{\%} (n = 8). The octanol/water partition coefficient of 68Ga labeled NODAGA-HPBCD was found to be −3.07 ± 0.11. In vivo dynamic and ex vivo biodistribution studies using control BALB/c mice revealed that 68Ga labeled NODAGA-HPBCD was mainly excreted by the kidney, due to its hydrophilic properties that has been proved by the partition coefficient. The accumulation of the radiotracer in abdominal organs was low, and no uptake was found in the brain. In conclusion 68Ga labeled NODAGA-HPBCD was successfully produced for the first time and tested in vitro and in vivo. The synthesized NODAGA-HPBCD was characterized and labeled with 68Ga successfully. Overall, the outcome of our study indicates that the in vivo behavior of radiolabeled cyclodextrins can be examined by PET techniques, thus these derivatives are suitable for further pharmacokinetic measurements.",
keywords = "Ga, Hydroxypropyl-beta-cyclodextrin, Pharmacokinetics, Positron emission tomography",
author = "Istv{\'a}n Hajdu and J{\'a}nos Angyal and Dezső Szikra and Istv{\'a}n Kert{\'e}sz and Milo Malanga and {\'E}va Fenyvesi and Lajos Szente and M. Vecserny{\'e}s and I. B{\'a}cskay and J. V{\'a}radi and P{\'a}lma Feh{\'e}r and Zolt{\'a}n Ujhelyi and G{\'a}bor Vasv{\'a}ri and {\'A}gnes Ruszny{\'a}k and Gy{\"o}rgy Trencs{\'e}nyi and Ferenc Fenyvesi",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.ejps.2018.12.001",
language = "English",
volume = "128",
pages = "202--208",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - Radiochemical synthesis and preclinical evaluation of 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD)

AU - Hajdu, István

AU - Angyal, János

AU - Szikra, Dezső

AU - Kertész, István

AU - Malanga, Milo

AU - Fenyvesi, Éva

AU - Szente, Lajos

AU - Vecsernyés, M.

AU - Bácskay, I.

AU - Váradi, J.

AU - Fehér, Pálma

AU - Ujhelyi, Zoltán

AU - Vasvári, Gábor

AU - Rusznyák, Ágnes

AU - Trencsényi, György

AU - Fenyvesi, Ferenc

PY - 2019/2/1

Y1 - 2019/2/1

N2 - A new renaissance started in the research and application of cyclodextrins a few years ago. 2-Hydroxypropyl-beta-cyclodextrin (HPBCD) is used in the formulation of drugs and recently orphan designation was granted for the treatment of Niemann-Pick disease, type C. HPBCD is considered to be safe, but the exact mechanism of action and side effects are not completely explained. Labeled cyclodextrin derivatives are required to reveal the biological activity and in vivo distribution by imaging techniques. The aims of our study were to synthetize the 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD) and test the pharmacokinetic properties and in vivo distribution of this radiolabeled molecule. p-NCS-benzyl-NODA-GA (NODAGA) was conjugated to the 6-deoxy-6-monoamino-(2-hydroxypropyl)-β-cyclodextrin (NH2-HPBCD). The product (NODAGA-HPBCD) was analyzed by analytical RP-HPLC and verified with high resolution mass spectrometry. In the next step the NODAGA-HPBCD was labeled with Gallium-68 (68Ga). The 68Ga labeled NODAGA-HPBCD (68Ga-NODAGA-HPBCD) was characterized and the radiochemical purity (RCP%), partition coefficient (log P values), and in vitro stability was determined. Thereafter in vivo distribution and pharmacokinetic properties of 68Ga-NODAGA-HPBCD was monitored by positron emission tomography (PET). NODAGA-HPBCD was purified by preparative RP-HPLC and the purity was better than 98%. The radiochemical purity of the 68Ga-NODAGA-HPBCD was higher than 98%, the specific activity was 17.62 ± 2.43 GBq/μmol, and the decay corrected yield was 76.54 ± 6.12% (n = 8). The octanol/water partition coefficient of 68Ga labeled NODAGA-HPBCD was found to be −3.07 ± 0.11. In vivo dynamic and ex vivo biodistribution studies using control BALB/c mice revealed that 68Ga labeled NODAGA-HPBCD was mainly excreted by the kidney, due to its hydrophilic properties that has been proved by the partition coefficient. The accumulation of the radiotracer in abdominal organs was low, and no uptake was found in the brain. In conclusion 68Ga labeled NODAGA-HPBCD was successfully produced for the first time and tested in vitro and in vivo. The synthesized NODAGA-HPBCD was characterized and labeled with 68Ga successfully. Overall, the outcome of our study indicates that the in vivo behavior of radiolabeled cyclodextrins can be examined by PET techniques, thus these derivatives are suitable for further pharmacokinetic measurements.

AB - A new renaissance started in the research and application of cyclodextrins a few years ago. 2-Hydroxypropyl-beta-cyclodextrin (HPBCD) is used in the formulation of drugs and recently orphan designation was granted for the treatment of Niemann-Pick disease, type C. HPBCD is considered to be safe, but the exact mechanism of action and side effects are not completely explained. Labeled cyclodextrin derivatives are required to reveal the biological activity and in vivo distribution by imaging techniques. The aims of our study were to synthetize the 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD) and test the pharmacokinetic properties and in vivo distribution of this radiolabeled molecule. p-NCS-benzyl-NODA-GA (NODAGA) was conjugated to the 6-deoxy-6-monoamino-(2-hydroxypropyl)-β-cyclodextrin (NH2-HPBCD). The product (NODAGA-HPBCD) was analyzed by analytical RP-HPLC and verified with high resolution mass spectrometry. In the next step the NODAGA-HPBCD was labeled with Gallium-68 (68Ga). The 68Ga labeled NODAGA-HPBCD (68Ga-NODAGA-HPBCD) was characterized and the radiochemical purity (RCP%), partition coefficient (log P values), and in vitro stability was determined. Thereafter in vivo distribution and pharmacokinetic properties of 68Ga-NODAGA-HPBCD was monitored by positron emission tomography (PET). NODAGA-HPBCD was purified by preparative RP-HPLC and the purity was better than 98%. The radiochemical purity of the 68Ga-NODAGA-HPBCD was higher than 98%, the specific activity was 17.62 ± 2.43 GBq/μmol, and the decay corrected yield was 76.54 ± 6.12% (n = 8). The octanol/water partition coefficient of 68Ga labeled NODAGA-HPBCD was found to be −3.07 ± 0.11. In vivo dynamic and ex vivo biodistribution studies using control BALB/c mice revealed that 68Ga labeled NODAGA-HPBCD was mainly excreted by the kidney, due to its hydrophilic properties that has been proved by the partition coefficient. The accumulation of the radiotracer in abdominal organs was low, and no uptake was found in the brain. In conclusion 68Ga labeled NODAGA-HPBCD was successfully produced for the first time and tested in vitro and in vivo. The synthesized NODAGA-HPBCD was characterized and labeled with 68Ga successfully. Overall, the outcome of our study indicates that the in vivo behavior of radiolabeled cyclodextrins can be examined by PET techniques, thus these derivatives are suitable for further pharmacokinetic measurements.

KW - Ga

KW - Hydroxypropyl-beta-cyclodextrin

KW - Pharmacokinetics

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=85058379653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058379653&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2018.12.001

DO - 10.1016/j.ejps.2018.12.001

M3 - Article

C2 - 30521943

AN - SCOPUS:85058379653

VL - 128

SP - 202

EP - 208

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -